特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959708

EB-101:新薬の考察と2030年までの市場予測

EB 101- Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
EB-101:新薬の考察と2030年までの市場予測
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

EB-101は、承認された治療法のない希少疾患である劣性ジストロフィー表皮水疱症(RDEB)治療のための自己遺伝子修正細胞療法であり、現在第III相の臨床試験が行われています。

当レポートは、米国、ドイツ、フランス、イタリア、スペイン、英国、日本の主要7ヶ国におけるEB-101の市場を調査し、2030年までの展望を示したもので、医薬品の概要、市場の評価、SWOT分析、競合企業各社のプロファイル、他の新たな治療薬などの情報を提供しています。

調査範囲

  • 製品の説明、作用機序、投与量と投与方法、 研究開発活動を含む包括的な製品概要
  • 規制機関の承認手続きのマイルストーンなど開発活動の詳細
  • 米国 、欧州、日本における医薬品研究開発の詳細
  • EB-101に関する有効期限を含めた特許情報
  • 2030年までのEB-101の売上高予測
  • 開発後期段階(第III相)にある新たな治療薬の総合的な情報
  • アナリストの考察とSWOT分析

レポートのハイライト

  • 今後表皮水疱症治療薬の市場シナリオは、世界各国で進められている研究開発と医療費の増加に伴って大きく変わり、市場規模の拡大により参入する製薬会社が増える見通しです。
  • 企業と研究者は、EB-101の優位性を高める機会を模索しています。現在開発中の治療法では、病状を治療/改善するための新たなアプローチが焦点となっています。
  • EB-101と競合する新たな競合製品が登場しており、近い将来市場に大きな影響を与えると思われます。

当レポートが対応している主な疑問点

  • EB-101を開発しているのはどの企業か。
  • EB-101の開発に利用されている技術は何か。
  • EB-101の製品タイプ、投与経路、作用機序はどのようなものか。
  • 臨床試験の状況と完了日はいつか。
  • EB-101の開発に関連する主な協力、合併、買収、ライセンシングなどの動きはどうなっているのか。
  • EB-101に付与された主な指定は何か。
  • EB-101の予測市場シナリオはどのようなものか。
  • EB-101のこれまでの経緯はどのようなものか。
  • 米国、ドイツ、フランス、イタリア、スペイン、英国、日本でのEB-101の売上予測はどうか。
  • 利用可能な他の新製品は何か。またこれらの製品とはどのような形で競合するのか。
  • 現在開発後期段階にある新たな治療薬は何か。

目次

第1章 医薬品の概要

  • 製品の詳細
  • 作用機序
  • 投薬と管理
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国の市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場での競合

第6章 他の新たな治療薬

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 EB 101, Description
  • Table 2 EB 101, Clinical Trial Description
  • Table 3 EB 101, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of EB 101
  • Figure 2 Patent Details, EB 101
  • Figure 3 EB 101, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 EB 101, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 EB 101, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 EB 101, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0059

"EB 101- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Epidermolysis bullosa in 7 Major Markets. A detailed picture of the EB 101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

EB-101 is an autologous, gene-corrected cell therapy currently being investigated in the pivotal Phase 3 VIITALTM study for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy. The EB-101 VIITALTM study is a multi-center, randomized clinical trial enrolling 10 to 15 RDEB patients with approximately 30 large, chronic wound sites treated in total. Treatment with EB-101 involves using gene transfer to deliver COL7A1 genes into a patient's own skin cells (keratinocytes and its progenitors) and transplanting them back to the patient to enable normal Type VII collagen expression and facilitate wound healing. Abeona produces EB-101 for the VIITALTM study at its fully-functional gene and cell therapy manufacturing facility in Cleveland, OH. In a Phase 1/2a clinical trial, EB-101 provided durable wound healing for RDEB patients lasting 2+ to 5+ years, including for the largest, most challenging wounds that affect the majority of the RDEB population.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around EB 101.
  • The report contains forecasted sales for EB 101 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Epidermolysis bullosa.
  • The report also features the SWOT analysis with analyst insights and key findings of EB 101.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EB 101 Analytical Perspective by DelveInsight

  • In-depth EB 101 Market Assessment

This report provides a detailed market assessment of EB 101 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • EB 101 Clinical Assessment

The report provides the clinical trials information of EB 101 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Epidermolysis bullosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence EB 101 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Epidermolysis bullosa are giving market competition to EB 101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of EB 101.
  • Our in-depth analysis of the forecasted sales data of EB 101 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EB 101.

Key Questions:

  • Which company is developing EB 101 along with the phase of the clinical study?
  • What is the technology utilized in the development of EB 101?
  • What is the product type, route of administration and mechanism of action of EB 101?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EB 101 development?
  • What are the key designations that have been granted to EB 101?
  • What is the forecasted market scenario of EB 101?
  • What is the history of EB 101 and what is its future?
  • What is the forecasted sales of EB 101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to EB 101?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.